# US 2016/0257946 A1 · NON-NATURAL AMINO ACID tRNA SYNTHETASES FOR PARA-METHYLAZIDO-L-PHENYLALANINE

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257946 A1
- Document ID: US20160257946A1
- Status: Published application
- Kind: A1
- Application number: 15/028,396
- Filed: 2014-10-10
- Published: 2016-09-08
- Earliest claimed: 2013-10-11
- Assignees: Sutro Biopharma, Inc.
- Applicants: Sutro Biopharma, Inc.
- Inventors: Erik S. Zimmerman; Christopher Thanos
- Web page: https://patentgrep.com/patent/US20160257946A1

## CPC

- C12N 9/93: {Ligases (6)}
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- C07K 1/02: in solution {(C07K1/003, C07K1/006 take precedence)}
- C07K 16/32: against translation products of oncogenes
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C12Y 601/01: Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
- C12Y 601/01001: Tyrosine-tRNA ligase (6.1.1.1)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Y: ENZYMES

## Abstract

The invention provides methods and compositions for a mutein aminoacyl-tRNA synthetase that preferentially charges a tRNA with a non-natural amino acid. Also provided are methods for incorporating the non-natural amino acid, para-methylazido-L-phenylalanine into a protein and further conjugating a biologically active adduct to the para-methylazido-L-phenylalanine.

## Claims

### Claim 1

A composition comprising an aminoacyl-tRNA synthetase (RS) wherein the RS:
i) preferentially aminoacylates to a degree of greater than 90% a tRNA with para-methylazido-L-phenylalanine (pAMF) compared to the 20 common naturally occurring amino acids;
ii) has a sequence identity of over 80% to Methanococcus jannaschii tyrosyl tRNA synthetase (TyrRS) having SEQ NO:1; and
iii) using SEQ ID NO: 1 as a reference sequence, has:
a) at position L65 amino acid: A or V;
b) at position F108 amino acid: Y or W;
c) at position D158 amino acid: A;
d) at position Y32 amino acid: T or V or A; and
e) at position I159 amino acid: S or G or V.

### Claim 2 (depends on 1)

The composition of claim 1, having an amino acid substitution at position Q109 selected from the group of amino acids consisting of L or M or I.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the RS has a sequence identity of at least 90% of SEQ ID NO:1 and has amino acid substitutions selected from the group consisting of:
i) Y32T, 1,65A, F108Y, Q109L and I159S;
ii) Y32V, L65A, F108W, Q109M and I159G;
iii) Y32A, L65V, F108W and I159G;
iv) Y32V, L65V, F108Y and I159V;
v) Y32T, L65V, F108W and I159S; and
vi) Y32V, L65V, F108W, G109I and I159S.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the RS is selected from the group of amino acid sequences consisting of SEQ ID NO: 2 and SEQ ID NO: 3.

### Claim 5

A polynucleotide encoding aminoacyl-tRNA synthetase (RS) wherein the RS:
i) preferentially aminoacylates to a degree of greater than 90% a tRNA with para-methylazido-L-phenylalanine (pAMF) compared to the 20 common naturally occurring amino acids;
ii) has a sequence identity of over 80% to Methanococcus jannaschii tyrosyl tRNA synthetase (TyrRS) having SEQ ID NO: 1; and
iii) using SEQ ID NO: 1 as a reference sequence, has:
a) at position L65 amino acid: A or V;
b) at position F108 amino acid: Y or W;
c) at position D158 amino acid: A;
d) at position Y32 amino acid: T or V or A; and
e) at position I159 amino acid: S or G or V.

### Claim 6 (depends on 5)

The polynucleotide of claim 5, having an amino acid substitution at position Q109 selected from the group of amino acids consisting of L or M or I.

### Claim 7 (depends on 5)

The polynucleotide of claim 5, wherein the RS has a sequence identity of at least 90% of SEQ ID NO: 1 and has amino acid substitutions selected from the group consisting of:
i) Y32T, L65A, F108Y, Q109L, and I159S;
ii) Y32V, L65A, F108W, Q109M and I159G;
iii) Y32A, L65V, F108W and I159G;
iv) Y32V, L65V, F108Y and I159V;
v) Y32T, L65V, F108W and I159S; and
vi) Y32V, L65V, F108W, G109I and I159S.

### Claim 8 (depends on 5)

The polynucleotide of claim 5, wherein the RS is selected from the group of amino acid sequences consisting of SEQ ID NO: 2 and SEQ ID NO: 3.

### Claim 9

A cell free protein synthesis system for selectively incorporating para-methylazido-L-phenylalanine (pAMF) into a protein of interest, the system comprising:
a) a cell free extract of bacteria having biologically functioning tRNA, amino acids and ribosomes necessary for cell free protein synthesis;
b) a polynucleotide having a coding region encoding the protein of interest and including a suppression codon selectively positioned within its coding region;
c) methylazido-L-phenylalanine in a concentration sufficient to permit selective incorporation of pAMF into the protein of interest;
d) a tRNA able to be charged with pAMF and complementary to the suppression codon of the protein of interest; and
e) an aminoacyl-tRNA synthetase (RS) wherein the RS:
i) preferentially aminoacylates to a degree of greater than 90% a tRNA with pAMF compared to the 20 common naturally occurring amino acids;
ii) has a sequence identity of over 80% to Methanococcus jannaschii tyrosyl tRNA synthetase (TyrRS) having SEQ ID NO:1; and
iii) using SEQ ID NO:1 as a reference sequence, has:
a) at position L65 amino acid: A or V;
b) at position F108 amino acid: Y or W;
c) at position D158 amino acid: A;
d) at position Y32 amino acid: T or V or A; and
e) at position I159 amino acid: S or G or V.

### Claim 10 (depends on 9)

The cell free protein synthesis system of claim 9, wherein the RS has an amino acid substitution at position Q109 selected from the group of amino acids consisting of L or M or I.

### Claim 11 (depends on 9)

The cell free protein synthesis system of claim 9, wherein the RS has a sequence identity of at least 90% of SEQ ID NO: 1 and has amino acid substitutions selected from the group consisting of:
i) Y32T, L65A, F108Y, Q109L, and I159S;
ii) Y32V, L65A, F108W, Q109M and I159G;
iii) Y32A, L65V, F108W and I159G;
iv) Y32V, L65V, F108Y and I159V;
v) Y32T, L65V, F108W and I159S; and
vi) Y32V, L65V, F108W, G109I and I159S.

### Claim 12 (depends on 9)

The cell free protein synthesis system of claim 9, wherein the RS is selected from the group of amino acid sequences consisting of SEQ ID NO: 2 and SEQ ID NO 3.

### Claim 13 (depends on 9)

The cell free protein synthesis system of claim 9, wherein the cell free extract has an active oxidative phosphorylation system.

### Claim 14 (depends on 9)

The cell free protein synthesis system of claim 9, wherein the protein of interest is an antibody or antibody fragment.

### Claim 15

A method for selectively incorporating para-methylazido-L-phenylalanine (pAMF) into a protein of interest, the method comprising the steps of:
a) combining a cell free extract of bacteria having containing biologically functioning tRNA, amino acids and ribosomes necessary for cell free protein synthesis with the following reagents:
i) a polynucleotide having a coding region encoding the protein of interest and including a suppression codon selectively positioned within its coding region;
ii) methylazido-L-phenylalanine in a concentration sufficient to permit selective incorporation of pAMF into the protein of interest;
iii) a tRNA able to be charged with pAMF and complementary to the suppression codon of the protein of interest; and
iv) an aminoacyl-tRNA synthetase (RS) wherein the RS:
preferentially aminoacylates to a degree of greater than 90%, a tRNA with pAMF compared to the 20 common naturally occurring amino acids;
has a sequence identity of over 80% to Methanococcus jannaschii tyrosyl tRNA synthetase (TyrRS) having SEQ ID NO: 1; and
using SEQ ID NO: 1 as a reference sequence, has:
a) at position L65 amino acid: A or V;
b) at position F108 amino acid: Y or W;
c) at position D158 amino acid: A;
d) at position Y32 amino acid: T or V or A; and
e) at position I159 amino acid: S or G or V; and
b) incubating the combination of step (a) under conditions permitting selective incorporation of pAMF into the protein of interest.

### Claim 16 (depends on 15)

The method of claim 15, wherein the RS further has an ammo acid substitution at position Q109 selected from the group of amino acids consisting of L or M or I.

### Claim 17 (depends on 15)

The method of claim 15, wherein the RS has sequence identity of at least 90% of SEQ ID NO:1 and further has an amino acid substitution selected from the group of substitutions consisting of:
i) Y32T, L65A, F108Y, Q109L, and I159S;
ii) Y32 V; L65A, F108W, Q109M, and I159G;
iii) Y32A, L65V, F108W, and I159G;
iv) Y32V, L65V, F108Y, and I159V;
v) Y32T, L65V, F108W, and I159S; and
vi) Y32V, L65V, F108W, G109I, and I159S.

### Claim 18 (depends on 15)

The method of claim 15, wherein the RS is selected from he group of amino acid sequences consisting of SEQ ID NOs: 2 and 3.

### Claim 19 (depends on 15)

The method of claim 15, wherein the cell free extract has an active oxidative phosphorylation system.

### Claim 20 (depends on 15)

The method of claim 15, wherein the protein of interest is an antibody or antibody fragment.

### Claim 21 (depends on 15)

The method of claim 15, further comprising conjugating a biologically active adduct to the pAMF of the protein of interest.

### Claim 22 (depends on 21)

The method of claim 21, wherein the conjugation is by a 1,3-cycloaddition of an azide with a strained alkyne.
